[HTML][HTML] Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective …
…, J Cooper, M Khan, J Vidler, H Kakkassery… - The Lancet …, 2021 - thelancet.com
Background The efficacy and safety profiles of vaccines against SARS-CoV-2 in patients with
cancer is unknown. We aimed to assess the safety and immunogenicity of the BNT162b2 (…
cancer is unknown. We aimed to assess the safety and immunogenicity of the BNT162b2 (…
[HTML][HTML] Immunogenicity of SARS-CoV-2 vaccines in patients with cancer
H Kakkassery, E Carpenter, PEM Patten… - Trends in Molecular …, 2022 - cell.com
Transmission of the SARS-CoV-2 virus and its corresponding disease (COVID-19) has
been shown to impose a higher burden on cancer patients than on the general population. …
been shown to impose a higher burden on cancer patients than on the general population. …
[HTML][HTML] B cells in patients with melanoma: implications for treatment with checkpoint inhibitor antibodies
…, S Crescioli, K Hussein, H Kakkassery… - Frontiers in …, 2021 - frontiersin.org
The contributions of the humoral immune response to melanoma are now widely recognized,
with reports of positive prognostic value ascribed to tumor-infiltrating B cells (TIL-B) and …
with reports of positive prognostic value ascribed to tumor-infiltrating B cells (TIL-B) and …
Interim results of the safety and immune-efficacy of 1 versus 2 doses of COVID-19 vaccine BNT162b2 for cancer patients in the context of the UK vaccine priority …
…, R Graham, J Cooper, M Khan, J Vidler, H Kakkassery… - MedRxiv, 2021 - medrxiv.org
Background The efficacy and safety profile of vaccines against severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) have not been definitively established in …
syndrome coronavirus 2 (SARS-CoV-2) have not been definitively established in …
Abstract PO1-13-04: Distinct immune signatures discriminate between patients defined as exceptional survivors of metastatic breast cancer compared to those with …
H Kakkassery, T Alaguthurai, Z Kozik, P Buckley, R Lu… - Cancer Research, 2024 - AACR
Background: "Atypical responders" can encompass three sub- categories of patients: "exceptional
responders" (those with an unusually favourable treatment response), "rapid …
responders" (those with an unusually favourable treatment response), "rapid …
986 Local and lymphoid immune surveillance mechanisms in “exceptional survivors” of stage IV breast cancers following standard of care chemo-and targeted …
H Kakkassery, T Alaguthurai, R Graham, E Carpenter… - 2022 - jitc.bmj.com
Background Breast cancer patients with metastatic disease can exhibit rapid disease
progression, disease stabilisation or partial responses of varying duration. However, for reasons …
progression, disease stabilisation or partial responses of varying duration. However, for reasons …
Abstract PD2-01: Local and lymphoid immune surveillance mechanisms in “exceptional survivors” of stage 4 cancers following standard of care chemo-and targeted …
H Kakkassery, T Alaguthurai, R Graham, E Carpenter… - Cancer Research, 2023 - AACR
Breast cancer patients with advanced metastatic disease can exhibit rapid disease progression,
disease stabilisation or partial responses of varying duration. However, for reasons that …
disease stabilisation or partial responses of varying duration. However, for reasons that …
Boosting of Waned Humoral and Cellular Responses to SARS-CoV-2 Variants of Concern Among Patients with Cancer
…, C Arman, E Pollock, C Gousis, H Kakkassery… - Cancer research …, 2022 - AACR
This study offers longitudinal insight into the impact of three SARS-CoV-2 vaccinations on
humoral and cellular immunity in patients with solid cancers, patients with hematologic …
humoral and cellular immunity in patients with solid cancers, patients with hematologic …
Abstract P2-20-02: Enrichment of atypical memory double negative (CD27—IgD—) tumour infiltrating b cells following neoadjuvant chemotherapy for early-stage …
…, T Alaguthurai, F Hossain, R Graham, H Kakkassery… - Cancer Research, 2023 - AACR
Background: Humoral immune responses have previously been associated with improved
outcomes, with B cell infiltrates able to independently predict pathologic complete response to …
outcomes, with B cell infiltrates able to independently predict pathologic complete response to …
[HTML][HTML] 972 Enrichment of atypical memory double negative (CD27—IgD—) tumour infiltrating B cells following neoadjuvant chemotherapy for early-stage breast …
…, T Alaguthurai, F Hossain, R Graham, H Kakkassery… - 2022 - jitc.bmj.com
Background Humoral immune responses have previously been associated with improved
outcomes, with B cell infiltrates able to independently predict pathologic complete response to …
outcomes, with B cell infiltrates able to independently predict pathologic complete response to …
